Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
about
Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pHDegradation of the LDL receptors by PCSK9 is not mediated by a secreted protein acted upon by PCSK9 extracellularlyThe proprotein convertase PCSK9 induces the degradation of low density lipoprotein receptor (LDLR) and its closest family members VLDLR and ApoER2Self-association of human PCSK9 correlates with its LDLR-degrading activityRegulation of epithelial sodium channel trafficking by proprotein convertase subtilisin/kexin type 9 (PCSK9)The PCSK9 decadeTherapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primatesHypercholesterolemia, low density lipoprotein receptor and proprotein convertase subtilisin/kexin-type 9PCSK9 and triglyceride-rich lipoprotein metabolismProprotein convertase subtilisin/kexin type 9: from the discovery to the development of new therapies for cardiovascular diseasesFeedback regulation of cholesterol uptake by the LXR-IDOL-LDLR axisTrafficking Dynamics of PCSK9-Induced LDLR Degradation: Focus on Human PCSK9 Mutations and C-Terminal DomainMolecular biology of PCSK9: its role in LDL metabolismStructural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemiaThe self-inhibited structure of full-length PCSK9 at 1.9 A reveals structural homology with resistin within the C-terminal domainMolecular basis for LDL receptor recognition by PCSK9Antagonism of Secreted PCSK9 Increases Low Density Lipoprotein Receptor Expression in HepG2 CellsA proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primatesA PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivoA century of cholesterol and coronaries: from plaques to genes to statinsPCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the futureLipoprotein(a) catabolism is regulated by proprotein convertase subtilisin/kexin type 9 through the low density lipoprotein receptorStructural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptorCatalytic activity is not required for secreted PCSK9 to reduce low density lipoprotein receptors in HepG2 cellsCCC- and WASH-mediated endosomal sorting of LDLR is required for normal clearance of circulating LDLIDOL stimulates clathrin-independent endocytosis and multivesicular body-mediated lysosomal degradation of the low-density lipoprotein receptor.Proprotein convertase subtilisin/kexin type 9 (PCSK9) gene is a risk factor of large-vessel atherosclerosis stroke.A proprotein convertase subtilisin-like/kexin type 9 (PCSK9) C-terminal domain antibody antigen-binding fragment inhibits PCSK9 internalization and restores low density lipoprotein uptake.Genetic Architecture of Familial Hypercholesterolaemia.Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies.Structure-based kernels for the prediction of catalytic residues and their involvement in human inherited disease.High-dose atorvastatin causes a rapid sustained increase in human serum PCSK9 and disrupts its correlation with LDL cholesterolAlirocumab inhibits atherosclerosis, improves the plaque morphology, and enhances the effects of a statin.Correlation of PCSK9 gene polymorphism with cerebral ischemic stroke in Xinjiang Han and Uygur populations.The proprotein convertase subtilisin/kexin type 9 (PCSK9) active site and cleavage sequence differentially regulate protein secretion from proteolysis.Living the PCSK9 adventure: from the identification of a new gene in familial hypercholesterolemia towards a potential new class of anticholesterol drugs.PCSK9 and LDLR degradation: regulatory mechanisms in circulation and in cells.A two-step binding model of PCSK9 interaction with the low density lipoprotein receptorEffects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.
P2860
Q24297165-54B04A7D-DD6F-41EA-89D3-CF7BE3300023Q24298534-9961F03B-FE3A-4639-BE97-8250259CDE50Q24301411-27884268-FA26-4039-B00B-B525C11F6019Q24306591-78D5A3BE-4B99-4362-A142-255F5AD05DCAQ24312859-57E1893E-9E7E-4768-A6E2-7B3634F94E53Q24615397-A2294576-F2D2-4A05-AB52-2DC851080CB2Q24646644-584471F1-6E35-4A09-9BE2-B3A5D49FFE6EQ26786549-485C5163-C915-4996-977B-9F36D14728EEQ26796287-63C591AA-C07F-4123-BFE1-5142F08C5FE4Q27009477-113B1720-EF67-442A-ADCB-382BD96B3CBFQ27026250-A3711283-63EA-4485-AB59-35F67A79F322Q27339783-26F78C23-05F3-4A67-9F26-28ABFDA7A739Q27488922-47E12A2E-1008-4F2F-AB9D-669C0ED7D44FQ27644461-B7668615-A4F5-4756-8D24-26CFA4F44F21Q27647905-18DB0978-449D-4269-9DA6-DAD366DEBCCDQ27649779-0406E75A-6108-4E4D-B7C9-DFDA8DF0B60DQ27653836-487E2E00-989C-460E-AB43-67D343E8E47FQ27655476-101A5CA7-86E2-49B8-8EF7-22DF8FF0B747Q27665195-1B2B795F-E351-4BE6-B89D-C036CCF806E1Q28080618-818FF844-6823-45D2-B59D-291778B7E4F2Q28083595-260B1878-126A-421B-A22C-53EBE9FF13BAQ28258969-5BC22771-5D62-42FD-B0EC-773D77DAF255Q28292154-A37C8A1B-8D9F-4872-A27E-223EE85DEB3AQ28304381-2C77FE75-FF49-4755-8103-6B4AE5ECF726Q28975614-394D66C4-EF36-415F-84F5-2956C09FA0B8Q30538763-C170139A-52EE-4E3D-ACF1-EA80D0BC7055Q33302900-D5C3F664-461E-4B3A-A898-62EBD21DF9B3Q33532964-8C95DF1E-27F0-4D1F-84AF-63878CA67898Q33559233-E4925B8F-F953-47AE-B6F3-2B6B07B8699FQ33577851-4EA8D8F7-6FAD-4E3E-BD98-A929CEA85268Q33818871-F8EC570E-9316-4A87-A373-8CE4E01C8B49Q34046936-230B46A3-2718-4636-BE35-0C92C22D94D0Q34053143-B7018346-979E-4246-98EA-94B635139A7CQ34238694-D9743032-F8B1-4F59-A97D-86DD7B7AAE1BQ34306545-BFCDDD55-C86A-4912-9D33-858E03BA8490Q34355679-100E08E1-CEDD-41AA-975C-5777C464813DQ34430377-C98C231C-5537-485E-AC23-B0467B87E76DQ34433146-F3E71AA6-1912-4634-BEDB-B4E9C99D6261Q34568486-FAB7A87C-74F8-4B2A-8418-90E7E2B4E6BFQ34662589-0012F8C2-FC41-43A6-8902-EE9194E28CDB
P2860
Secreted PCSK9 decreases the number of LDL receptors in hepatocytes and in livers of parabiotic mice
description
2006 nî lūn-bûn
@nan
2006 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@ast
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en-gb
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@nl
type
label
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@ast
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en-gb
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@nl
prefLabel
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@ast
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en-gb
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@nl
P2093
P2860
P921
P3181
P356
P1476
Secreted PCSK9 decreases the n ...... d in livers of parabiotic mice
@en
P2093
David E Curtis
Heidi B Prather
Jay D Horton
Markey C McNutt
Norma N Anderson
Rita Garuti
Robert E Hammer
Sahng Wook Park
Thomas A Lagace
P2860
P304
P3181
P356
10.1172/JCI29383
P407
P577
2006-11-01T00:00:00Z